Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
47 hedge funds and large institutions have $149M invested in Inozyme Pharma in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 15 closing their positions.
110% more capital invested
Capital invested by funds: $71.2M → $149M (+$78.2M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
29% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 14
5.13% more ownership
Funds ownership: 73.54% → 78.68% (+5.1%)
6% less funds holding
Funds holding: 50 → 47 (-3)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$14.1M |
| 2 |
VA
VR Adviser
New York
|
+$11.8M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$7.08M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$6.29M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$5.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$4.14M |
| 2 |
BlackRock
New York
|
-$1.95M |
| 3 |
JP Morgan Chase
New York
|
-$1.35M |
| 4 |
State Street
Boston,
Massachusetts
|
-$609K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$291K |
INZY Hedge Fund Activity: Q2 2022 in Review
47 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q2 2022, worth a combined $149M — up 110% from $71.2M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of INZY and 13 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 18 added.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $14.1M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $4.14M sold.
- 47 institutional investors held Inozyme Pharma (INZY) as of Q2 2022, down from 50 in Q1 2022.
- Funds reported $149M of Inozyme Pharma stock for Q2 2022, up 110% quarter-over-quarter.
- 13 funds opened new Inozyme Pharma positions in Q2 2022 and 15 closed out, a net change of -2 holders.
- The largest Inozyme Pharma buyer in Q2 2022 was Deep Track Capital, an estimated $14.1M added.
- The largest Inozyme Pharma seller in Q2 2022 was Suvretta Capital Management, an estimated $4.14M sold.
Based on aggregated 13F filings for Q2 2022.